Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001600620-25-000106
Filing Date
2025-11-04
Accepted
2025-11-04 06:06:12
Documents
61
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q auph-20250930.htm   iXBRL 10-Q 980644
2 EX-31.1 auph-2025q3exx311.htm EX-31.1 10711
3 EX-31.2 auph-2025q3exx312.htm EX-31.2 10848
4 EX-32.1 auph-2025q3exx321.htm EX-32.1 5263
5 EX-32.2 auph-2025q3exx322.htm EX-32.2 5271
  Complete submission text file 0001600620-25-000106.txt   5305848

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20250930.xsd EX-101.SCH 30036
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT auph-20250930_cal.xml EX-101.CAL 70564
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT auph-20250930_def.xml EX-101.DEF 134850
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20250930_lab.xml EX-101.LAB 522301
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20250930_pre.xml EX-101.PRE 338947
64 EXTRACTED XBRL INSTANCE DOCUMENT auph-20250930_htm.xml XML 675733
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36421 | Film No.: 251446246
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)